Chemotherapeutic agents—including topoisomerase inhibitors and alkylating agents—as well as targeted therapies such as cyclin-dependent kinase (CDK) inhibitors, Aurora kinase inhibitors, and epidermal growth factor receptor (EGFR) inhibitors, have been shown to promote immune cells senescence in various cancers, including cervical, colorectal, and breast cancer (73–75). Here, EGFR is linked to breast carcinoma.